InflaRx (IFRX) Free Cash Flow (2016 - 2026)
InflaRx (IFRX) posted Free Cash Flow of -$8.6 million for Q1 2026, down 50.47% sequentially from -$5.7 million in Q4 2025, and up 41.33% YoY from -$6.1 million in Q1 2025.
InflaRx (IFRX) Free Cash Flow (2016 - 2026) Analysis & Trends
InflaRx has reported Free Cash Flow for 11 years, with the latest figure at -$8.6 million in Q1 2026.
- Quarterly Free Cash Flow rose 41.33% year-over-year to -$8.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$33.4 million (up 34.77% YoY) and the FY2025 annual result came in at -$40.0 million, up 23.91% from the prior year.
- Free Cash Flow eased to -$8.6 million in Q1 2026 per IFRX's latest filing, from -$5.7 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$3.2 million in Q3 2022 and troughed at -$16.1 million in Q1 2024.
- A 5-year average of -$10.5 million and a median of -$11.3 million in 2023 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2022 and 2023: Free Cash Flow jumped 72.88% in 2022, then sank 128.74% in 2023.
- Over 5 years, Free Cash Flow stood at -$5.2 million in 2022, then tumbled by 128.74% to -$11.8 million in 2023, then declined by 8.07% to -$12.8 million in 2024, then surged by 55.1% to -$5.7 million in 2025, then slumped by 50.47% to -$8.6 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$8.6 million, -$5.7 million, and -$10.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn | -2.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.64 Mn |
| Mar 31, 2026 | -8.64 Mn |
| Dec 31, 2025 | -5.74 Mn |
| Dec 31, 2025 | -5.74 Mn |
| Sep 30, 2025 | -10.47 Mn |
| Sep 30, 2025 | -10.47 Mn |
| Jun 30, 2025 | -8.53 Mn |
| Jun 30, 2025 | -8.53 Mn |
| Mar 31, 2025 | -14.73 Mn |
| Mar 31, 2025 | -14.73 Mn |
| Dec 31, 2024 | -12.79 Mn |
| Dec 31, 2024 | -12.79 Mn |
| Sep 30, 2024 | -10.61 Mn |
| Sep 30, 2024 | -10.61 Mn |
| Jun 30, 2024 | -13.05 Mn |
| Jun 30, 2024 | -13.05 Mn |
| Mar 31, 2024 | -16.13 Mn |
| Mar 31, 2024 | -16.13 Mn |
| Dec 31, 2023 | -11.84 Mn |
| Dec 31, 2023 | -11.84 Mn |